project id: TCGA-PRAD; case submitter id: TCGA-KC-A4BO; source center: 23; state: released; a260 a280 ratio: 1.76; age at index: 55; days to birth: -20368; ethnicity: not hispanic or latino; gender: male; race: black or african american; vital status: Alive; year of birth: 1955; age at diagnosis: 20368; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 607.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; weight: 30.0; days to collection: 742; initial weight: 590.0; sample id: b27a31c6-4537-4871-ae5d-e4dab1321f24; sample submitter id: TCGA-KC-A4BO-01A; portion id: 04e9e095-3fd0-4fb9-a5f6-54bdb15c2726; portion submitter id: TCGA-KC-A4BO-01A-61; slide id: 6a5e6d29-3dea-451c-8ef2-0a15c5f797d6; slide submitter id: TCGA-KC-A4BO-01A-06-TSF; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 0.0; percent tumor cells: 80.0; percent tumor nuclei: 70.0; section location: TOP;